RS-2023-00218195

First-in-Class FLT3 Degrader Discovery Using PROTACs and Chemoproteomics

Yonsei University Industry-University Cooperation Foundation

ONCOLOGY | **Lead**

Product Type	Targeted protein degradation (TPD)
Indication	Acute Myeloid Leukemia
Target	FLT3 mutants resistant to the approved FLT3 inhibitor such as gilteritinib
MoA(Mechanism of Action)	• PROTAC (proteolysis-targeting chimera) is a bifunctional molecule composed of three parts: i) a ligand that binds to target protein, ii) a ligand for E3 ligase, and iii) a linker connecting two ligands. • PROTACs induces degradation of target protein by inducing proximity between target protein and E3 ligase.
Competitiveness	Overriding triple mutant (ITD/F671L/D835Y) of FLT3 by using conventional small molecule is challenging.
Development Stage	Lead compound development
Route of Administration	Intravenuous or oral (po) administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund